al102
ayala pharmaceuticalsceuticals,novartis
['al102', 'sarcoma']
ringside al102 for #desmoid part a results #esmo22 response: within 16 weeks, deepen with time tox: g3 uncommon, no g4/5 supports progression to open label dose expansion #sarcoma 
Medical Oncology Fellow @COBLH Sarcoma Unit | Sarcoma proteomics PhD ProCan @CMRI_AUS |@myESMO YOC | AYA | Rare cancers | MedEd | ????????